Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) and Certara (NASDAQ:CERT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.
Profitability
This table compares Firefly Neuroscience and Certara’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Firefly Neuroscience | -565.40% | -94.68% | -73.51% |
| Certara | -16.75% | 3.86% | 2.65% |
Earnings & Valuation
This table compares Firefly Neuroscience and Certara”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Firefly Neuroscience | $1.14 million | 15.82 | -$19.88 million | ($0.63) | -1.83 |
| Certara | $418.84 million | 2.97 | -$1.60 million | ($0.45) | -18.12 |
Certara has higher revenue and earnings than Firefly Neuroscience. Certara is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Firefly Neuroscience has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Certara has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.
Insider and Institutional Ownership
5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 74.0% of Certara shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by company insiders. Comparatively, 1.1% of Certara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations for Firefly Neuroscience and Certara, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
| Certara | 1 | 6 | 4 | 1 | 2.42 |
Certara has a consensus target price of $8.28, suggesting a potential upside of 1.54%. Given Certara’s stronger consensus rating and higher probable upside, analysts clearly believe Certara is more favorable than Firefly Neuroscience.
Summary
Certara beats Firefly Neuroscience on 12 of the 15 factors compared between the two stocks.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
About Certara
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
